U
TVTX icon

UBS’s Travere Therapeutics TVTX Stock Holding History

UBS’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Sell
500
-17,200
-97% -$202K ﹤0.01% 9492
2014
Q2 		$208K Buy
+17,700
New +$240K ﹤0.01% 5115

Other funds holding TVTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

UBS's TVTX Position: Q3 2014 in Review

UBS increased its Travere Therapeutics (TVTX) stake by 142% in Q3 2014, buying an estimated $5K and bringing the position to 725 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #9185.

UBS first reported a position in TVTX in Q1 2014 and has held it in 3 quarters since. The position peaked at $805K in Q1 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

  • UBS held 725 shares of Travere Therapeutics worth $7K as of Q3 2014.
  • UBS bought 425 Travere Therapeutics shares in Q3 2014, an estimated $5K.
  • Travere Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9185 holding.
  • UBS first reported a position in Travere Therapeutics in Q1 2014 and has held it in 3 quarters since.
  • UBS's Travere Therapeutics position peaked at $805K in Q1 2014.
  • 60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.